Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
Items 1,001–1,038 of 1,038
Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver
Xia, M., Chandrasekaran, P., Rong, S., Fu, X., & Mitsche, M. A. (2021) · Journal of Lipid Research · doi:10.1194/jlr.ra120000856 · Cited by 60
“Similarly, increased DNL is present in individuals with insulin resistance and hepatic steatosis (33), and inhibition of this pathway reduces liver TGs by ∼30% (34–36).”
BackgroundMiyake, T., Abe, M., Tokumoto, Y., Hirooka, M., Furukawa, S., Kumagi, T., Hamada, M., Kawasaki, K., Tada, F., Ueda, T., et al. (2013) · Hepatology International · doi:10.1007/s12072-012-9345-8 · Cited by 59
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2013 · Cited by 59
“Especially in the fasted state, adipose tissue contributed 80% of fatty acid content to the plasma NEFA pool (9).”
BackgroundMcMahan, R. H., Porsche, C. E., Edwards, M. G., & Rosen, H. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159217 · Cited by 55
“In addition, elevated levels of the saturated palmitic acid (PA) and the mono-unsaturated oleic acid (OA) are found in NAFLD patients and make up a majority of the FFA in TAG [3,6].”
Kostrzewski, T., Snow, S., Battle, A. L., Peel, S., Ahmad, Z., Basak, J., Surakala, M., Bornot, A., Lindgren, J., Ryaboshapkina, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02616-x · Cited by 52
Azzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52
“An increase in de novo lipogenesis (DNL) and lipid remodelling has been reported in multiple studies of subjects with NAFLD [7e9] and shown to be a significant factor in NASH pathophysiology [10].”
BackgroundCharidemou, E., Ashmore, T., Li, X., McNally, B. D., West, J. A., Liggi, S., Harvey, M., Orford, E., & Griffin, J. L. (2019) · JCI Insight · doi:10.1172/jci.insight.124819 · Cited by 52
“Multiple rounds of activation of acetyl-CoA to malonyl-CoA, transferral to FAS, and addition to the lengthening carbon chain generate palmitate (4).”
Background5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
Nasiri, M., Nikolaou, N., Parajes, S., Krone, N. P., Valsamakis, G., Mastorakos, G., Hughes, B., Taylor, A., Bujalska, I. J., Gathercole, L. L., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1149 · Cited by 50
Insulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
“In humans TAG synthesis is mainly fueled by circulating FA, which highlights the impact of FA uptake in the contribution toward hepatic steatosis in NAFLD (77).”
GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
Liu, J., Wang, G., Jia, Y., & Xu, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2580 · Cited by 48
“Regulation on hepatic lipid metabolism Hepatic lipid equilibrium is maintained by influx of FAs into liver, FAs β-oxidation, de novo lipogenesis and secretion of very low-density lipoprotein (VLDL) [15].”
BackgroundInfluentialDual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease
Karl, M., Hasselwander, S., Zhou, Y., Reifenberg, G., Kim, Y. O., Park, K., Ridder, D. A., Wang, X., Seidel, E., Hövelmeyer, N., et al. (2022) · Hepatology · doi:10.1002/hep.32428 · Cited by 44
“A major proportion of hepatic fat accumulating in the liver under the HFD arises from visceral adipose tissue, represented by EAT, due to exhaustion of fat storage capability.[23] In accordance with uniform EAT hypertrophy (Figures 1A, S1D), expression of regulators of adipocyte differentiation, peroxysome proliferato…”
BackgroundPPP2R5C couples hepatic glucose and lipid homeostasis
Cheng, Y.-S., Seibert, O., Klöting, N., Dietrich, A., Straßburger, K., Fernández-Veledo, S., Vendrell, J. J., Zorzano, A., Blüher, M., Herzig, S., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005561 · Cited by 43
“The liver uptakes a substantial part of this glucose, removing it from circulation, and converting it to glycogen for storage, or to lipids which are in part stored and in part resecreted as VLDL particles [1–3].”
BackgroundThe interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease
Poulsen, M. K., Nellemann, B., Stødkilde-Jørgensen, H., Pedersen, S. B., Grønbæk, H., & Nielsen, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3476 · Cited by 39
Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
McCommis, K. S., & Finck, B. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.017 · Cited by 39
“For instance, hyperinsulinemia in insulin-resistant states stimulates hepatic de novo lipogenesis,17 and this newly synthesized lipid comprises roughly 25% of the hepatic triglyceride accumulating in NAFLD.18 Insulin-resistant adipose tissue is linked to higher rates of basal lipolysis and thus exposure of the liver t…”
BackgroundInfluentialZhu, Z., Zhang, X., Pan, Q., Zhang, L., & Chai, J. (2023) · Liver Research · doi:10.1016/j.livres.2023.11.003 · Cited by 38
Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity
Lytle, K. A., Bush, N. C., Triay, J. M., Kellogg, T. A., Kendrick, M. L., Swain, J. M., Gathaiya, N. W., Hames, K. C., & Jensen, M. D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00875 · Cited by 35
Integrin-Linked Kinase Is Necessary for the Development of Diet-Induced Hepatic Insulin Resistance
Williams, A. S., Trefts, E., Lantier, L., Grueter, C. A., Bracy, D. P., James, F. D., Pozzi, A., Zent, R., & Wasserman, D. H. (2017) · Diabetes · doi:10.2337/db16-0484 · Cited by 35
“There was no difference in circulating 5 h–fasted plasma TGs (Fig.”
BackgroundInfluentialDesjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33
“38,39 ACLY sits upstream of acetyl-CoA carboxylase (ACC) in the DNL pathway, generating acetyl-CoA and oxaloac-etate, and is inhibited with BemA.”
Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity
Wijarnpreecha, K., Panjawatanan, P., Aby, E., Ahmed, A., & Kim, D. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.03.016 · Cited by 32
Fu, X., Fletcher, J. A., Deja, S., Inigo-Vollmer, M., Burgess, S. C., & Browning, J. D. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167442 · Cited by 30
“%) and [1,2-13 C 2 ]sodium β -hydroxybutyrate (98”
InfluentialKetogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation
Queathem, E. D., Moazzami, Z., Stagg, D. B., Nelson, A. B., Fulghum, K., Hayir, A., Seay, A., Gillingham, J. R., d’Avignon, D. A., Han, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads0535 · Cited by 30
Nonalcoholic fatty liver disease and metabolic syndrome in hypopituitary patients
Nyenwe, E. A., Williamson-Baddorf, S., Waters, B., Wan, J. Y., & Solomon, S. S. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181a84bde · Cited by 28
The hepatic lipidome and HNF4α and SHBG expression in human liver
Winters, S. J., Scoggins, C. R., Appiah, D., & Ghooray, D. T. (2020) · Endocrine Connections · doi:10.1530/ec-20-0401 · Cited by 28
Murine models provide insight to the development of non-alcoholic fatty liver disease
Reid, D. T., & Eksteen, B. (2015) · Nutrition Research Reviews · doi:10.1017/s0954422415000128 · Cited by 26
“Diets higher in saturated fat and cholesterol have been linked to patients with NAFLD and may influence the development of hepatic insulin resistance((23,24)).”
BackgroundIncreased visceral adipocyte lipolysis--a pathogenic role in nonalcoholic fatty liver disease?
Thörne, A., Löfgren, P., & Hoffstedt, J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0520 · Cited by 25
“The effect of noradrenaline on visceral fat FFA release was also about twice as high in patients with high liver fat accumulation.”
BackgroundInfluentialLu, S., Mott, J. L., & Harrison-Findik, D. D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.648212 · Cited by 24
“The increase in the uptake of free fatty acids by hepatocytes and de novo fatty acid synthesis lead to fat accumulation in the livers of NAFLD patients (2).”
BackgroundMetabolic injury of hepatocytes promotes progression of NAFLD and AALD
Carvalho-Gontijo, R., Han, C., Zhang, L., Zhang, V., Hosseini, M., Mekeel, K., Schnabl, B., Loomba, R., Karin, M., Brenner, D. A., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1755316 · Cited by 23
Jackson, K. C., Wohlers, L. M., Valencia, A. P., Cilenti, M., Borengasser, S. J., Thyfault, J. P., & Spangenburg, E. E. (2011) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h11-099 · Cited by 21
Maseko, T., Elkalaf, M., Peterová, E., Lotková, H., Staňková, P., Melek, J., Dušek, J., Žádníková, P., Čížková, D., Bezrouk, A., et al. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5342 · Cited by 21
“Clinical studies have demon‑ strated that patients with NAFLd have an increased capacity to mobilize FFAs from adipose tissue to the liver, particularly when they suffer from insulin resistance (23,24).”
BackgroundWeight loss in MASLD restores the balance of liver fatty acid sources
Lambert, J. E., Ramos-Roman, M. A., Valdez, M. J., Browning, J. D., Rogers, T., & Parks, E. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci174233 · Cited by 20
“Our original study of lipid labeling in MASLD patients demonstrated a strong association between the magnitude of stored lipid and the unlabeled lipid in VLDL-TG (12).”
Self-citationRafiei, H., Yeung, M., Kowalski, S., Krystal, G., & Elisia, I. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234300 · Cited by 21
Wang, Y., Bian, X., Wan, M., Dong, W., Gao, W., Yao, Z., & Guo, C. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-023-00775-8 · Cited by 20
“FAS plays a critical role in hepatic lipogenesis and it was estimated that approximately 26% of the fat in the liver is from de novo lipogenesis in NAFLD patients [39].”
BackgroundTelgenkamp, I., Kusters, Y. H. A. M., Schalkwijk, C. G., Houben, A. J. H. M., Kooi, M. E., Lindeboom, L., Bons, J. A. P., Schaper, N. C., Joris, P. J., Plat, J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02378 · Cited by 18
Adipose Tissue Dysfunction and Metabolic Diseases: The Role of Vitamin D/Vitamin D Receptor Axis
Cimini, F. A., Sentinelli, F., Oldani, A., Barchetta, I., & Cavallo, M. G. (2025) · doi:10.20944/preprints202509.1434.v1 · Cited by 14
Huang, Z., Li, L., Dudley, K., Xiao, L., Huang, G., Subramaniam, V. N., Chen, C., Crawford, R., & Xiao, Y. (2025) · BME Frontiers · doi:10.34133/bmef.0181 · Cited by 10
“Given the critical role of elevated free fatty acids (FFAs) in MASLD pathogenesis [ 3 ], most in vitro models simulate the disease by incorporating high concentrations of FFAs in the culture media to induce lipid accumulation in hepatocytes [ 4 ].”
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
RNA interference to target lipid disorders
Rondinone, C. M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ff861e · Cited by 2
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.